LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Начало・Списък с акции・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Затворен

СекторЗдравеопазване

3.48 -3.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.45

Максимум

3.61

Ключови измерители
By Trading Economics
Приходи	8.3M -18M
Продажби	9.6M 10M
P/E Средно за сектора	22.5 51.415
EPS	-0.1
Марж на печалбата	-177.89
Служители	69
EBITDA	8M -19M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+260.11% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-70M 840M
Предишно отваряне	6.81
Предишно затваряне	3.48

Настроения в новините

By Acuity

34%

66%

69 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

0.7658 / N/A Подкрепа & съпротива

CytomX Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.05.2026 г., 23:53 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17.05.2026 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

UOB: Transactions Part of Group's Capital Reallocation Strategy

17.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

UOB: Share Sale Agreements Entered With Singland Properties

17.05.2026 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Fund Stake Acquisition via Internal Resources

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire Stake for $389 Million

17.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16.05.2026 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16.05.2026 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

CytomX Therapeutics Inc Прогноза

Ценова цел

By TipRanks

260.11% нагоре

12-месечна прогноза

Среден 13 USD 260.11%

Висок 16 USD

Нисък 11 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за CytomX Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на CytomX Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.7658 / N/AПодкрепа & съпротива

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

69 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.